These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32311513)

  • 1. Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?
    Carlson RG; Daniulaityte R; Silverstein SM; Nahhas RW; Martins SS
    Int J Drug Policy; 2020 Apr; 79():102722. PubMed ID: 32311513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.
    Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Zaragoza A; Moeller A; Carlson RG
    Drug Alcohol Depend; 2019 Nov; 204():107574. PubMed ID: 31568934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methamphetamine Use and Its Correlates among Individuals with Opioid Use Disorder in a Midwestern U.S. City.
    Daniulaityte R; Silverstein SM; Crawford TN; Martins SS; Zule W; Zaragoza AJ; Carlson RG
    Subst Use Misuse; 2020; 55(11):1781-1789. PubMed ID: 32441178
    [No Abstract]   [Full Text] [Related]  

  • 4. "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl.
    Silverstein SM; Daniulaityte R; Martins SS; Miller SC; Carlson RG
    Int J Drug Policy; 2019 Dec; 74():76-83. PubMed ID: 31563098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes and experiences with fentanyl contamination of methamphetamine: exploring self-reports and urine toxicology among persons who use methamphetamine and other drugs.
    Daniulaityte R; Ruhter L; Juhascik M; Silverstein S
    Harm Reduct J; 2023 Apr; 20(1):54. PubMed ID: 37081499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD.
    Park JN; Weir BW; Allen ST; Chaulk P; Sherman SG
    Harm Reduct J; 2018 Jul; 15(1):34. PubMed ID: 29976195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and correlates of non-fatal overdose among people who use drugs: findings from rapid assessments in Massachusetts, 2017-2019.
    Shrestha S; Stopka TJ; Hughto JMW; Case P; Palacios WR; Reilly B; Green TC
    Harm Reduct J; 2021 Aug; 18(1):93. PubMed ID: 34461922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.
    Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Carlson RG
    J Subst Use Addict Treat; 2023 Apr; 147():208973. PubMed ID: 36804351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study.
    Carroll JJ; Marshall BDL; Rich JD; Green TC
    Int J Drug Policy; 2017 Aug; 46():136-145. PubMed ID: 28578864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
    Carter J; Zevin B; Lum PJ
    Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania.
    Pizzicato LN; Johnson CC; Viner KM
    Subst Abus; 2020; 41(3):301-306. PubMed ID: 31644397
    [No Abstract]   [Full Text] [Related]  

  • 15. Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021.
    Del Pozo B; Atkins D; Andraka-Christou B; Wightman R; Clark MH; Huynh P; Ray B
    Drug Alcohol Depend Rep; 2023 Mar; 6():. PubMed ID: 36777895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndemic factors associated with non-fatal overdose among young opioid users in New York City.
    Guarino H; Frank D; Quinn K; Kim D; Gile K; Ruggles K; Friedman SR; Mateu-Gelabert P
    Front Public Health; 2023; 11():1195657. PubMed ID: 37435512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying a potential protective effect of buprenorphine on fatality risk during acute fentanyl exposures.
    Dai Z; Abate MA; Winstanley E; Kraner JC; Lundstrom E; Mock AR; Smith GS
    J Subst Use Addict Treat; 2024 Mar; 158():209252. PubMed ID: 38070651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence.
    Sherman SG; Morales KB; Park JN; McKenzie M; Marshall BDL; Green TC
    Int J Drug Policy; 2019 Jun; 68():46-53. PubMed ID: 30991301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Mobile Overdose Response Program: A mobile, low-threshold opioid use disorder treatment model in Philadelphia.
    Lowenstein M; Popova E; Jalloh A; Mazzella S; Botcheos D; Bertocchi J; Westfahl S; Garcia KP; Truchil R; Chertok J
    J Subst Use Addict Treat; 2024 Sep; 164():209429. PubMed ID: 38857828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.